NCT02807558: A reported trial by Syros Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02807558 |
|---|---|
| Title | A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 20, 2016 |
| Completion date | Jan. 25, 2023 |
| Required reporting date | Jan. 25, 2026, midnight |
| Actual reporting date | Sept. 25, 2024 |
| Date last checked at ClinicalTrials.gov | June 3, 2026 |
| Days late | None |